The results showed that Rapamycin, Dasatinib, Sunitinib and Saracatinib had a higher IC50 in the low TLS score group of patients, in contrast to AKT inhibitor VII (Figure 8I–8M). Here, AKT1 is linked to Tumor Lysis Syndrome.